These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17828812)

  • 41. Adaptive immune responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Curr Top Microbiol Immunol; 2013; 369():243-62. PubMed ID: 23463204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response.
    Bode JG; Brenndörfer ED; Häussinger D
    Biol Chem; 2008 Oct; 389(10):1283-98. PubMed ID: 18713016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The intracellular inhibition of HCV replication represents a novel mechanism of action by the innate immune Lactoferrin protein.
    Picard-Jean F; Bouchard S; Larivée G; Bisaillon M
    Antiviral Res; 2014 Nov; 111():13-22. PubMed ID: 25193851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Feld JJ; Hoofnagle JH
    Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection.
    Xiang Y; Tang JJ; Tao W; Cao X; Song BL; Zhong J
    J Virol; 2015 Jul; 89(13):6805-16. PubMed ID: 25903345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The hepatitis C virus persistence: how to evade the immune system?
    Pavio N; Lai MM
    J Biosci; 2003 Apr; 28(3):287-304. PubMed ID: 12734407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate immune responses to hepatitis C virus.
    Schoggins JW; Rice CM
    Curr Top Microbiol Immunol; 2013; 369():219-42. PubMed ID: 23463203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of hepatic innate immunity by hepatitis C virus.
    Horner SM; Gale M
    Nat Med; 2013 Jul; 19(7):879-88. PubMed ID: 23836238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes.
    Liu Y; Zou Z; Zhu B; Hu Z; Zeng P; Wu L
    Hepat Mon; 2015 May; 15(5):e28473. PubMed ID: 26045710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes.
    Grünvogel O; Colasanti O; Lee JY; Klöss V; Belouzard S; Reustle A; Esser-Nobis K; Hesebeck-Brinckmann J; Mutz P; Hoffmann K; Mehrabi A; Koschny R; Vondran FWR; Gotthardt D; Schnitzler P; Neumann-Haefelin C; Thimme R; Binder M; Bartenschlager R; Dubuisson J; Dalpke AH; Lohmann V
    Gastroenterology; 2018 Jun; 154(8):2237-2251.e16. PubMed ID: 29535029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C virus' initial encounters: mechanisms of innate immunity.
    Eksioglu EA
    Front Biosci (Landmark Ed); 2012 Jan; 17(1):281-99. PubMed ID: 22201744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment failure in hepatitis C: mechanisms of non-response.
    Tai AW; Chung RT
    J Hepatol; 2009 Feb; 50(2):412-20. PubMed ID: 19070928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Innate detection of hepatitis B and C virus and viral inhibition of the response.
    Yi Z; Chen J; Kozlowski M; Yuan Z
    Cell Microbiol; 2015 Sep; 17(9):1295-303. PubMed ID: 26243406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
    Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
    J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.
    Rau SJ; Hildt E; Himmelsbach K; Thimme R; Wakita T; Blum HE; Fischer R
    Hepatology; 2013 Jan; 57(1):23-36. PubMed ID: 22814930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes.
    Friborg J; Ross-Macdonald P; Cao J; Willard R; Lin B; Eggers B; McPhee F
    PLoS One; 2015; 10(3):e0121734. PubMed ID: 25826356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental models to study the immunobiology of hepatitis C virus.
    Jo J; Lohmann V; Bartenschlager R; Thimme R
    J Gen Virol; 2011 Mar; 92(Pt 3):477-93. PubMed ID: 21148278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HCV and interferon: viral strategies for evading innate defence mechanisms in the virus-host battle.
    Capobianchi MR; Abbate I; Cappiello G; Solmone M
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S22-4. PubMed ID: 12655342
    [No Abstract]   [Full Text] [Related]  

  • 59. Immune responses to HCV and other hepatitis viruses.
    Park SH; Rehermann B
    Immunity; 2014 Jan; 40(1):13-24. PubMed ID: 24439265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection.
    Okamoto M; Oshiumi H; Azuma M; Kato N; Matsumoto M; Seya T
    J Immunol; 2014 Mar; 192(6):2770-7. PubMed ID: 24532585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.